GSK’s move doesn’t end litigation around Zantac as other drugmakers are still facing trials, including Boehringer Ingelheim GmbH, which is facing a jury trial in Oakland.

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

Boehringer Ingelheim has not announced any major settlements ... allowed plaintiffs to present crucial expert testimony that Zantac caused cancer. The drug companies had sought to keep that ...

Zantac, first sold in the US in 1983 ... another major US pharmaceutical company, and Germany-based Boehringer Ingelheim. In recent years, however, the drug's popularity declined.

Boehringer Ingelheim is the exception. It has not announced any major settlements. A drug under the name of Zantac 360, which contains no ranidine, is still being currently sold.

Pfizer has agreed to settle most of the Zantac cases against it in state court, according to its most recent financial statement, and Sanofi in April announced that it was settling about 4,000 cases.